These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20501373)

  • 1. [Thymidylate synthase expression and therapeutic effect analysis of pemetrexed in advanced lung adenocarcinoma].
    Wang ZK; Hu Y; Zhao H; Fu C
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):978-80. PubMed ID: 20501373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
    Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
    Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
    Igawa S; Ryuge S; Wada M; Otani S; Maki S; Takakura A; Katono K; Sasaki J; Sato Y; Masuda N
    Chemotherapy; 2012; 58(4):313-20. PubMed ID: 23147191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Sun JM; Han J; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2011 Aug; 6(8):1392-9. PubMed ID: 21716147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.
    Chang MH; Ahn JS; Lee J; Kim KH; Park YH; Han J; Ahn MJ; Park K
    Lung Cancer; 2010 Sep; 69(3):323-9. PubMed ID: 20061047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression.
    Gomez HL; Santillana SL; Vallejos CS; Velarde R; Sanchez J; Wang X; Bauer NL; Hockett RD; Chen VJ; Niyikiza C; Hanauske AR
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):832-8. PubMed ID: 16467096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.
    Lee SH; Noh KB; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kim CH; Kang KH; In KH
    Lung Cancer; 2013 Jul; 81(1):102-8. PubMed ID: 23523421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
    Righi L; Papotti MG; Ceppi P; Billè A; Bacillo E; Molinaro L; Ruffini E; Scagliotti GV; Selvaggi G
    J Clin Oncol; 2010 Mar; 28(9):1534-9. PubMed ID: 20177021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of pemetrexed plus platinum for chemotherapy-naive advanced non-small cell lung cancer].
    Duan JC; Wu MN; Zhao J; An TT; Yang L; Bai H; Wang ZJ; Zhuo ML; Wang SH; Wang YY; Liu XH; Wang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):97-101. PubMed ID: 22455964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
    Scagliotti GV; Selvaggi G
    Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.
    Kasai D; Ozasa H; Oguri T; Miyazaki M; Uemura T; Takakuwa O; Kunii E; Ohkubo H; Maeno K; Niimi A
    Anticancer Res; 2013 May; 33(5):1935-40. PubMed ID: 23645741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemetrexed disodium (Eli Lilly).
    Norman P
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1611-22. PubMed ID: 11763166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positioning pemetrexed in the treatment of ovarian cancer.
    Ledermann JA; Stebbing J
    Eur J Cancer; 2009 May; 45(8):1330-2. PubMed ID: 19264477
    [No Abstract]   [Full Text] [Related]  

  • 16. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated clinical information on multitargeted antifolates in lung cancer.
    Scagliotti GV; Ceppi P; Capelletto E; Novello S
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S35-40. PubMed ID: 19362945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
    Shimizu T; Nakanishi Y; Nakagawa Y; Tsujino I; Takahashi N; Nemoto N; Hashimoto S
    Anticancer Res; 2012 Oct; 32(10):4589-96. PubMed ID: 23060591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis.
    Wang L; Wang R; Pan Y; Sun Y; Zhang J; Chen H
    BMC Cancer; 2014 Mar; 14():205. PubMed ID: 24641970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
    Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
    Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.